Radiopharm Theranostics (ASX:RAD) Ending Cash Position: A$-7.32 Mil (As of Jun. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

What is Radiopharm Theranostics Ending Cash Position?

Radiopharm Theranostics ASX:RAD Ending Cash Position is A$-7.32 Mil as of Jun. 2025. The stock has 5 warning signs investors should review.

Radiopharm Theranostics's Ending Cash Position for the quarter that ended in Jun. 2025 was A$-7.32 Mil.

Radiopharm Theranostics's quarterly Ending Cash Position increased from Jun. 2024 (A$0.00 Mil) to Dec. 2024 (A$36.44 Mil) but then declined from Dec. 2024 (A$36.44 Mil) to Jun. 2025 (A$-7.32 Mil).

Radiopharm Theranostics's annual Ending Cash Position increased from Jun. 2023 (A$11.70 Mil) to Jun. 2024 (A$18.58 Mil) and increased from Jun. 2024 (A$18.58 Mil) to Jun. 2025 (A$29.12 Mil).

Radiopharm Theranostics Ending Cash Position Related Terms

Radiopharm Theranostics Ending Cash Position Historical Data

* Premium members only.

The historical data trend for Radiopharm Theranostics's Ending Cash Position can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Radiopharm Theranostics Ending Cash Position Chart

Radiopharm Theranostics Annual Data
Trend Jun22 Jun23 Jun24 Jun25
Ending Cash Position
26.98 11.70 18.58 29.12

Radiopharm Theranostics Semi-Annual Data
Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25
Ending Cash Position Get a 7-Day Free Trial 0.00 1.89 0.00 36.44 -7.32

Radiopharm Theranostics Ending Cash Position Calculation

Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. It is equal to the Beginning Cash Position plus the Net Change in Cash.

Radiopharm Theranostics's Ending Cash Position for the fiscal year that ended in Jun. 2025 is calculated as

Ending Cash Position= Beginning Cash Position+Net Change in Cash
=18.574+10.543
=29.12

Radiopharm Theranostics's Ending Cash Position for the quarter that ended in Jun. 2025 is calculated as

Ending Cash Position=Beginning Cash Position+Net Change in Cash
=0+-7.32
=-7.32

Frequently Asked Questions Learn more about Ending Cash Position →
What does a Ending Cash Position of A$-7.32 Mil mean?
Radiopharm Theranostics (ASX:RAD) has a Ending Cash Position of A$-7.32 Mil as of Jun. 2025. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Radiopharm Theranostics and its competitors.
Is Radiopharm Theranostics' Ending Cash Position too high?
Radiopharm Theranostics' current Ending Cash Position is A$-7.32 Mil.
How does Radiopharm Theranostics' Ending Cash Position compare to VRTX and REGN?
Radiopharm Theranostics' Ending Cash Position of A$-7.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Ending Cash Position for a Biotechnology company?
A good Ending Cash Position depends on the Biotechnology industry context. However, Ending Cash Position should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Ending Cash Position mean?
A high Ending Cash Position can signal that a stock is expensive relative to its fundamentals. Ending Cash Position is the cash and cash equivalents balance at the end of the accounting period, as indicated on the Cash Flow statement. View historical data on Radiopharm Theranostics and its competitors. Radiopharm Theranostics's current Ending Cash Position is A$-7.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Radiopharm Theranostics stock overvalued right now?
Radiopharm Theranostics (ASX:RAD) has a current Ending Cash Position of A$-7.32 Mil. The current Ending Cash Position is A$-7.32 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Ending Cash Position calculated?
Ending Cash Position is calculated from a company's financial statements. For Radiopharm Theranostics (ASX:RAD), the current Ending Cash Position is A$-7.32 Mil as of Jun. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Radiopharm Theranostics Business Description

Other Exchanges RADX:USA
Address 62 Lygon Street, Suite 1, Level 3, Carlton South, Melbourne, VIC, AUS, 3053
Radiopharm Theranostics Ltd is an Australian-based clinical-stage radiotherapeutics company targeting cancer. The company has a pipeline of approximately four licensed platform technologies, with diagnostic and therapeutic applications at both the pre-clinical and clinical stages of development. The company is engaged in research, development, and commercialization of health technologies.